Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at Stifel Nicolaus

Stifel Nicolaus initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $86.00 price objective on the stock.

A number of other analysts also recently issued reports on JSPR. TD Cowen assumed coverage on Jasper Therapeutics in a research report on Monday, March 18th. They issued an outperform rating for the company. Royal Bank of Canada initiated coverage on shares of Jasper Therapeutics in a report on Thursday, March 28th. They issued an outperform rating and a $70.00 target price for the company. HC Wainwright reiterated a buy rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Wednesday, May 15th. Oppenheimer reissued an outperform rating and issued a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Jasper Therapeutics in a research note on Tuesday, June 18th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus price target of $67.00.

Jasper Therapeutics Trading Up 3.1 %

Shares of NASDAQ JSPR opened at $22.70 on Thursday. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01. The firm’s 50-day moving average price is $23.12 and its 200-day moving average price is $19.54. The stock has a market capitalization of $341.86 million, a price-to-earnings ratio of -4.03 and a beta of 2.24.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.23. On average, equities analysts predict that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Ieq Capital LLC purchased a new position in shares of Jasper Therapeutics during the fourth quarter valued at $43,000. Monaco Asset Management SAM bought a new position in Jasper Therapeutics during the 4th quarter worth about $197,000. Virtu Financial LLC purchased a new position in Jasper Therapeutics during the 1st quarter valued at about $306,000. Fernwood Investment Management LLC raised its holdings in shares of Jasper Therapeutics by 8.8% in the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics in the 1st quarter valued at about $599,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.